Mall of America

Radisson Blu Mall of America Unveils New Offering: The Wellness Rooms, with lululemon's MIRROR

Retrieved on: 
Thursday, May 5, 2022
Mall of America, Hypergymnasia, Skyway, Mall, MIRROR, Health, Boxing, View, Yoga, Multimedia, General manager, Interior design

BLOOMINGTON, Minn., May 5, 2022 /PRNewswire/ -- Radisson Blu Mall of America today announced its latest addition to the hotel's health and wellness offerings, introducing dedicated guest rooms equipped with an in-room MIRROR. The Wellness Room, with lululemon's MIRROR, provides guests with unlimited access to the state-of-the-art fitness experience during their stay, all from the comfort of their own room. As travelers seek more convenient, higher-end fitness amenities, this new package is the perfect addition to Radisson Blu Mall of America's health and wellness offerings designed to meet travelers' needs.

Key Points: 
  • As travelers seek more convenient, higher-end fitness amenities, this new package is the perfect addition to Radisson Blu Mall of America's health and wellness offerings designed to meet travelers' needs.
  • lululemon's MIRROR is a "nearly invisible, smart home gym" that offers more than 10,000 classes available to stream around the clock.
  • "Radisson Blu Mall of America has a commitment to healthy living, and the addition of The Wellness Rooms, with lululemon's MIRROR, provides even greater options for our active guests," said Alex Francis, General Manager, Radisson Blu Mall of America.
  • Radisson Blu Mall of America is an elegant hotel offering the ultimate in style and convenience with direct access via skyway to the mall.

NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022

Retrieved on: 
Wednesday, May 4, 2022
Biotechnology, Health, Oncology, Cancer, COVID-19, Forward-looking statement, AMF, Cetuximab, Private Securities Litigation Reform Act, Mall of America, Radiation, Twitter, U.S. Securities and Exchange Commission, Company, Nanoparticle, Safety, HNSCC, Metastasis, Patient, Trial of the century, Nanotechnology, University, Webcast, Lung, Neoplasm, III, Annual report, LinkedIn, MD Anderson Cancer Center, SEC, Life, NBTXR3, SITC, Central nervous system, Risk, Nasdaq, Pharmaceutical industry, Euronext, Nanobiotix

Given the MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly, with immune checkpoint inhibitors.

Key Points: 
  • Given the MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly, with immune checkpoint inhibitors.
  • NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.
  • The company-sponsored phase I dose escalation and dose expansion study has produced favorable safety data and early signs of efficacy.
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.

New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting

Retrieved on: 
Monday, May 2, 2022
Research, Technology, Clinical Trials, Nanotechnology, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Cancer, COVID-19, ASCO, Head, AMF, Forward-looking statement, Cetuximab, Private Securities Litigation Reform Act, Mall of America, Radiation, Colorectal cancer, Twitter, U.S. Securities and Exchange Commission, NASDAQ, Neck, Company, Safety, Nanoparticle, Chemoradiotherapy, HNSCC, Metastasis, Patient, Trial of the century, Nanotechnology, University, American Society of Clinical Oncology, Neoplasm, Lung, III, Annual report, 2021 Essex County Council election, LinkedIn, Society, MD Anderson Cancer Center, NANO, SEC, Life, NBTXR3, SITC, Annual general meeting, Central nervous system, Risk, Nasdaq, Pharmaceutical industry, Euronext, Nanobiotix

Given the MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly, with immune checkpoint inhibitors.

Key Points: 
  • Given the MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly, with immune checkpoint inhibitors.
  • NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.
  • The company-sponsored phase I dose escalation and dose expansion study has produced favorable safety data and early signs of efficacy.
  • Given the Companys focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in strategic collaborations to expand development of the product candidate in parallel with its priority development pathways.

Fibromyalgia Pipeline Guide 2022: Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Pharmaceutical, Molecule, R, Target, Decision-making, Central nervous system, History, Mall of America, Company, Therapy, News, Research, SEC, Discovery, Medical device, Pharmaceutical industry, Fibromyalgia, Development

The "Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The Fibromyalgia pipeline guide also reviews key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

CJ 4DPLEX, B&B THEATRES EXTEND PARTNERSHIP TO ADD NEW SCREENX LOCATIONS ACROSS THE U.S.

Retrieved on: 
Thursday, April 28, 2022
Vibration, CJ Group, CEO, Academy Awards, Wind, Water, B&B Theatres, PLF, CJ CGV, Wesley Chapel, Top Gun: Maverick, Color, Snow, Technology, Lightning, History, Sound, Partnership, Mall of America, CJ ENM, Multimedia, Silver, B&B, SAG, City, House, Motion, Paramount Pictures, CJ, Screen, Edison Awards, Parasitism, Film, Entertainment, Red oak (disambiguation), ScreenX, Media, Technicolor

B&B Theatres has begun the rollout of new ScreenX theaters, starting in Athens, Georgia which opened in early April.

Key Points: 
  • B&B Theatres has begun the rollout of new ScreenX theaters, starting in Athens, Georgia which opened in early April.
  • Following Athens, B&B Theatres will open a new ScreenX auditorium at their Mall of America location in Bloomington, Minnesota in May.
  • Currently B&B Theatres has ScreenX locations in Liberty, Missouri, Overland Park, Kansas and Ridgeland, Mississippi.
  • "We're excited to extend our partnership with CJ 4DPLEX and continue the successful introduction of ScreenX to our audiences," said Brock Bagby, Executive Vice President of B&B Theatres.

CJ 4DPLEX, B&B THEATRES EXTEND PARTNERSHIP TO ADD NEW SCREENX LOCATIONS ACROSS THE U.S.

Retrieved on: 
Thursday, April 28, 2022
Vibration, CJ Group, CEO, Academy Awards, Wind, Water, B&B Theatres, PLF, CJ CGV, Wesley Chapel, Top Gun: Maverick, Color, Snow, Technology, Lightning, History, Sound, Partnership, Mall of America, CJ ENM, Silver, B&B, SAG, City, House, Motion, Paramount Pictures, CJ, Screen, Edison Awards, Parasitism, Film, Entertainment, Red oak (disambiguation), ScreenX, Media, Technicolor

B&B Theatres has begun the rollout of new ScreenX theaters, starting in Athens, Georgia which opened in early April.

Key Points: 
  • B&B Theatres has begun the rollout of new ScreenX theaters, starting in Athens, Georgia which opened in early April.
  • Following Athens, B&B Theatres will open a new ScreenX auditorium at their Mall of America location in Bloomington, Minnesota in May.
  • Currently B&B Theatres has ScreenX locations in Liberty, Missouri, Overland Park, Kansas and Ridgeland, Mississippi.
  • "We're excited to extend our partnership with CJ 4DPLEX and continue the successful introduction of ScreenX to our audiences," said Brock Bagby, Executive Vice President of B&B Theatres.

Color The Town Orange: Kubota Partners with Crayola Giving Kids Fun Ways to Dream Big

Retrieved on: 
Wednesday, April 20, 2022
Library, Travel, Farmer, Mall of America, Creativity, Learning, Kid, History of Crayola crayons, Technology, Heart, Student, Activity book, Imagination, General manager, Color, City, Multimedia, Partnership, Senior, View, Heavy equipment, Tourism, Toy, Kubota, Marketing, Crayola

GRAPEVINE, Texas, April 20, 2022 /PRNewswire/ -- Kubota Tractor Corporation and Crayola announced a partnership today to inspire the next generation of business owners, builders, farmers, do-it-yourselfers, and leaders by highlighting the unique and creative role that machines play in building and shaping communities.

Key Points: 
  • The brands will transform Crayola Experience family attractions into "Kubota Machine Adventures" in a five-market national takeover tour beginning in May.
  • Kubota and Crayola will also be creating the Kubota Coloring & Activity Book.
  • Kids ages 12-years-old and younger can submit an original drawing of Kubota equipment hard at work in their community, or color a downloadable template from KubotaCountryKids.com.
  • For product literature or dealer locations, contact: Kubota Tractor Corporation, 1000 Kubota Drive, Grapevine, TX 76051, (888) 4-KUBOTA [(888) 458-2682], Ext.

Hyperalgesia Drugs in Development Pipeline Guide 2022: By Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 20, 2022
Health, Pharmaceutical, Molecule, Research, News, Mall of America, Decision-making, R, SEC, History, Company, Therapy, Target, Central nervous system, Medical device, Pharmaceutical industry, Hyperalgesia

The "Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide evaluates Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Omnix Medical Starts Phase I Clinical Trial of Novel Anti-Infective; First Healthy Volunteers Dosed

Retrieved on: 
Tuesday, April 12, 2022
AMR, Pharmacokinetics, Clinical trial, Mortality, Acinetobacter baumannii, Bacteria, Research, Publication, CSO, QIDP, EIC, IIA, CEO, Prevalence, HIA, Technology, NIH, Gram-negative bacteria, Cell membrane, Infection, H2020, Mall of America, Patient, Brilacidin, Pharmaceutical industry, Vaccine

JERUSALEM, Israel, April 12, 2022 -- Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since March 28, 2022, six healthy volunteers have been administered the novel antimicrobial, which is based on a naturally occuring mechanism of action (MoA) leading to a targeted, effective destruction of the cell membrane of pathogens. The trial is being conducted in Groningen, The Netherlands. OMN6 is being evaluated in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of single and repeat IV infusion of the compound in healthy subjects. Results are expected by Q4, 2022.

Key Points: 
  • JERUSALEM, Israel, April 12, 2022 -- Omnix Medical , a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6.
  • OMN6 is being evaluated in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of single and repeat IV infusion of the compound in healthy subjects.
  • Dr. Niv Bachnoff, CSO of Omnix Medical, added We are thrilled about the progress of our first clinical trial.
  • Omnix Medical was founded on 2015 to address the urgent unmet need for new life-saving anti-infective drugs.

NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3

Retrieved on: 
Monday, April 11, 2022
Research, Technology, Clinical Trials, Nanotechnology, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Company, Private Securities Litigation Reform Act, Life, LinkedIn, Radiation, University, NBTXR3, NASDAQ, MD Anderson Cancer Center, Lung, III, Trial of the century, Forward-looking statement, Immunotherapy, NANO, Central nervous system, Survival, AACR, SEC, Nanoparticle, American Association, Neoplasm, Cancer, Metastasis, Risk, PD-1, Cetuximab, Monroe Dunaway Anderson, Nanotechnology, Association, Safety, Combination, Twitter, HNSCC, U.S. Securities and Exchange Commission, TIGIT, RNA transfection, COVID-19, Immunology, ICIS, AMF, SITC, Nasdaq, Annual report, Mall of America, Patient, Pharmaceutical industry, Vaccine, Nanobiotix, Euronext

Our view is that while new immunotherapy treatment modalities with the potential to improve outcomes for patients continue to emerge, they remain reliant upon an underlying immune response.

Key Points: 
  • Our view is that while new immunotherapy treatment modalities with the potential to improve outcomes for patients continue to emerge, they remain reliant upon an underlying immune response.
  • This new analysis, presented at AACR, assessed immune gene expression associated with multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT.
  • NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.
  • The company-sponsored phase I dose escalation and dose expansion study has produced favorable safety data and early signs of efficacy.